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RECENT evidence suggests that airway smooth muscle
cells (ASMC) actively participate in the airway inflam-
matory  process  in  asthma.  Interleukin–1b (IL–1b )
and tumour necrosis factor-a (TNF-a ) induce ASMC to
release  inflammatory  mediators  in  vitro.  ASMC
mediator release in vivo, however, may be influenced
by features of the allergic asthmatic phenotype. We
determined  whether;  (1)  allergic  asthmatic  serum
(AAS) modulates ASMC mediator release in response
to IL–1b and TNF-a , and (2) IL–1b /TNF-a prime ASMC
to release mediators in response to AAS. IL–5 and GM-
CSF were quantified by ELISA in culture supernatants
of;  (1)  ASMC  pre-incubated  with  either  AAS,  non-
allergic non-asthmatic serum (NAS) or Monomed™  (a
serum substitute )  and subsequently stimulated with
IL–1b and TNF-a and (2)  ASMC stimulated with IL–
1b /TNF-a and  subsequently  exposed  to  either  AAS,
NAS or Monomed™ . IL–1b and TNF-a induced GM-CSF
release  in  ASMC  pre-incubated  with  AAS  was  not
greater than that in ASMC pre-incubated with NAS or
Monomed™ .  IL–1b and  TNF-a ,  however,  primed
ASMC to release GM-CSF in response to human serum.
GM-CSF production following IL-1b /TNF-a and serum
exposure (AAS or NAS) was significantly greater than
that  following  IL–1b /TNF-a and  Monomed™   expo-
sure or IL–1b /TNF-a exposure only. Whilst the poten-
tiating effects of human serum were not specific to
allergic asthma, these findings suggest that the secre-
tory  capacity  of  ASMC  may  be  up-regulated  during
exacerbations of asthma, where there is evidence of
vascular leakage.
Key  words:  Asthma,  Airway  smooth  muscle,  Allergy,
Inflammation, Human serum, IL–1b, TNF-a, IL–5, GM-CSF
Introduction
It is now widely accepted that chronic inflammation
of the airways is one of the most important factors
contributing  to  abnormal  airway  smooth  muscle
(ASM)  function  in  asthma. Accumulating  evidence
suggests  that the inflammatory state of  the airways
induces  alterations  in  the  contractile  and  relaxant
apparatus  of  ASM.1,2 ASM  also  responds  to  it’s
inflammatory environment by undergoing structural
changes. Inflammatory cytokines, by inducing ASMC
hyperplasia and hypertrophy, contribute to thicken-
ing of the smooth muscle layer in the airway wall.3
Increased thickness of the smooth muscle layer is a
significant factor contributing to exaggerated airway
narrowing in asthma.4
Recently,  it  has  been  demonstrated  that  ASMC
synthesize several mediators in response to stimula-
tion with the pro-inflammatory cytokines IL–1b and
TNF-a.  Stimulation  of  ASMC  with  IL–1b leads  to
generation of prostaglandins E2 and I2 consequent to
the induction of cyclo-oxygenase–2 (COX–2) enzyme
expression.5,6ASMC also synthesize GM-CSF, IL–6, IL–
11 and several chemokines, including RANTES (regu-
lated upon  activation, normal T  cell  expressed and
secreted), eotaxin and IL–8 in response to IL–1b and/
or  TNF-a.7–13 In  addition  to  inducing  mediator
synthesis, TNF-a also induces expression of the adhe-
sion molecules ICAM–1 and VCAM–1 on ASMC.14
The ability  of ASMC to synthesize mediators and
express adhesion molecules in response to IL–1b and
TNF-a may be critical processes contributing to both
abnormal  ASM  function  and  perpetuation  of  the
airway inflammatory process in asthma. Whilst a wide
range of mediators synthesized by ASMC have been
identified, these mediators may not reflect the pattern
of  mediator synthesis by ASMC in the allergic  asth-
matic state in vivo. Allergic asthmatic serum (AAS) is
known to induce alterations in the sensitivity of ASM
to contractile and relaxant agonists.15,16 It is possible,
therefore,  that AAS  also  modulates ASMC  mediator
release. This possibility  is further supported by the
observation that IL–8, RANTES, and GM-CSF synthesis
by ASMC is susceptible to regulation by the immuno-
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13.7,10,12 The  aims  of  this  study  were  to  examine
cytokine  release  in  response  to  IL–1b/TNF-a by
human  ASMC  exposed  to  AAS  and  to  investigate
whether IL–1b/TNF-a prime ASMC to release cyto-
kines in response to AAS.
Materials and methods
Materials
AAS was obtained from a single  donor with severe
asthma and contained >2000IU/ml IgE. Non-allergic
non-asthmatic  serum  (NAS)  was  obtained  from  a
single  non-asthmatic  non-allergic  donor  and  con-
tained <20IU/ml IgE. Foetal Bovine Serum (FBS) and
Monomed™  were  obtained  from  CSL  Biosciences.
Dulbecco’s modified Eagle’s Medium (DMEM), Hanks’
balanced salt solution (HBSS) and all antibiotics were
obtained  from  Gibco  BRL.  IL–1b and TNF-a were
obtained  from  R&D  Systems  and  reconstituted  in
sterile  phosphate  buffered  saline  containing  0.1%
bovine serum albumin obtained from Sigma. Indom-
ethacin was obtained from Sigma and reconstituted in
5% sodium bicarbonate.
Induction of cytokine release by ASMC
A description of each protocol designed to answer the
study questions is provided in Table 1.
To  determine  whether  AAS  modulates  cytokine
stimulated  mediator  release  from  ASMC,  confluent
ASMC  were  incubated  with  AAS  and  then  serum
starved for either 24 or 72h prior to stimulation with
IL–1b and  TNF-a or  vehicle.  Control  treatments
included cells that were incubated with either NAS or
Monomed™ (Table 1: protocol 1). Following stimula-
tion with IL–1b and TNF-a, culture supernatants were
assayed for IL–5 and GM-CSF content.
In  separate  experiments,  the  influence  of  cell
density on the response to IL–1b and TNF-a in cells
pre-treated with AAS was also examined. ASMC were
initially plated at a range of densities in AAS. Control
cells were plated in either NAS or FBS. The cells were
incubated in the various serum treatments for only
24h  to  minimise  the  increase  in  cell  density  that
would occur as a result of cellular proliferation. ASMC
were serum starved for 24h and then stimulated with
IL–1b and TNF-a or  vehicle  (Table  1:  protocol  2).
Culture supernatants were assayed for IL–5 and GM-
CSF content following stimulation of the cells with
IL–1b and TNF-a.
To determine whether IL–1b/TNF-a prime ASMC to
release  mediators  in  response  to AAS, ASMC  were
stimulated  with  IL–1b/TNF-a or  vehicle  and  then
subsequently incubated with AAS. Control cells were
stimulated  with  IL–1b/TNF-a or  vehicle  and  then
subsequently  incubated  with  NAS  or  Monomed™
(Table  1:  protocol  3).  Given  that  COX  products
released in response to IL–1b/TNF-a may potentially
modulate  the  subsequent  response  to  the  various
serum treatments, these experiments were also per-
formed in the presence of the COX–1/COX–2 inhib-
itor, indomethacin. Indomethacin was added to the
cells  1h  before  and  during  stimulation  with  IL–
1b/TNF-aor vehicle and the various serum treatments.
Control treatments included cells where indomethacin
was; (1) not present at all, (2) present during cytokine
or  vehicle  stimulation only,  and  (3)  present  during
stimulation with the various serum treatments only.
Culture supernatants were assayed for IL–5 and GM-
CSF content following stimulation of the cells with IL–
1b/TNF-a or vehicle and following subsequent expo-
sure to the various serum treatments.
Cell culture
Human ASM was obtained from the bronchial airways
(3–6mm  internal  diameter) of  patients  undergoing
surgical resection for carcinoma or lung transplanta-
tion as previously described in detail by Hawker et
al.17 Briefly,  smooth muscle  bundles  were  isolated
from  the  bronchial  airways  and  placed  in  DMEM
supplemented with 10% FBS and antibiotics (20U/L
of penicillin, 20mg/ml of streptomycin, and 2.5mg/ml
of  amphotericin B) and maintained in  a humidified
atmosphere at 37°C in air/CO2 (95:5%, vol/vol). Fresh
medium was replaced every 5 days for the first 10–20
days. Once the ASMC had grown to confluence, they
were passaged and used between passages 3–7 for
experimentation. ASMC were characterised morpho-
logically  and  by  the  presence  of  smooth  muscle
specific a-actin as determined by immunohistochem-
istry.  All  experiments  were  carried  out  in  24-well
tissue culture plates in the presence of antibiotics. All
treatment  conditions  were  performed  in  triplicate,
except  the  indomethacin  experiments,  where  they
were performed in duplicate.
Viable cell counts
Viable cell counts were performed for experiments in
protocol 1 (Table 1). Cell counts were performed at
the end of the 24h or 72h serum starvation period in
wells  separate  from  those  used  for  induction  of
cytokine release. The adherent cells from duplicate or
triplicate  wells  were  harvested using  a  solution  of
trypsin (0.5% wt/vol in HBSS) containing 1 mM EDTA
and then counted with a hemocytometer. Cell viabil-
ity was determined with trypan blue exclusion; cells
that stained blue were counted as non-viable.
Cytokine assays
ASMC  supernatants  were  harvested  and  stored  at
–20°C until assayed for IL–5 and GM-CSF content by
M. B. Sukkar et al.
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.enzyme-linked  immunosorbent  assay  (ELISA).  Stan-
dards (rhIL–5 and rhGM-CSF) and capture/detection
monoclonal antibodies were obtained from PharMin-
gen  and  ELISAs  were  performed  according  to  the
manufacturer’s  directions.  Purified  rat  anti-human
GM-CSF (clone BVD2–23B6) and biotinylated rat anti-
human  GM-CSF  (clone  BVD2–21C11)  were  the
respective  capture  and  detection  monoclonal  anti-
bodies used for quantification of GM-CSF. Purified rat
anti-mouse/human  IL–5  (clone TRFK5)  and biotiny-
lated rat anti-human IL–5 (clone JES1–5A10) were the
respective  capture  and  detection  monoclonal  anti-
bodies used for  quantification of IL–5. The limit  of
detection was 5pg/ml and 10pg/ml for the GM-CSF
and IL–5 ELISAs, respectively.
Statistical analysis
In all protocols in Table 1, mean results for cytokine
release were determined from triplicate or duplicate
culture wells and then mean data for each treatment
obtained  from  all  cell  donors. Analyses  were  per-
formed  on  this  mean  data  and  significance  was
determined with ANOVA and Fisher’s protected least
squares  difference  (PLSD)  test.  Significance  was
defined as p£ 0.05 in all cases.
Ethical approval
Lung samples were used with the informed consent
of each patient and with the approval of the relevant
Area Health Service or Hospital Ethics Committee.
Results
Cytokine release by human ASMC pre-treated
with AAS prior to stimulation with IL–1b and
TNF-a
Exposure of ASMC to AAS did not alter the pattern of
cytokine release in response to stimulation with IL–
1b and TNF-a. ASMC pre-treated with AAS prior to
stimulation  with  IL–1b and TNF-a released  similar
amounts  of  GM-CSF  as  those cells  pre-treated with
NAS, and this was the case whether the cells were
serum  starved for  24  or 72h.  However,  whilst  the
serum  starvation  period  did  not  influence  the
response to the various serum treatments, there was a
trend  for  increased  GM-CSF  production  in  cells
starved for 24h compared to those starved for 72h
(Fig. 1a).
Interestingly, GM-CSF release by ASMC exposed to
either AAS or NAS and serum  starved for  72h was
significantly  less  than  that  in  their  Monomed™
treated  counterparts. A  trend  for  reduced  GM-CSF
release  following  AAS  or  NAS  exposure  vs Mono-
med™ exposure was also observed in cells that were
serum starved for 24h (Fig. 1a). In addition, there was
a trend for higher cell numbers in AAS or NAS treated
cultures compared with their Monomed™ counter-
parts (Fig. 1b). Together, these observations indicated
that IL–1b- and TNF-a stimulated GM-CSF release may
be inversely related to cell density. This is a phenom-
enon we had observed previously (Fig. 2).
ASMC did not release detectable amounts of IL–5 in
response  to  any  of  the  treatment  conditions  in
protocol 1.
Influence of cell density on cytokine release by
human ASMC pre-treated with AAS prior to
stimulation with IL–1b and TNF-a
Given that we had evidence to suggest that GM-CSF
production may  be  influenced  by  cell  density,  the
effect  of  AAS  on  ASMC  cytokine  release  was  also
examined under conditions where the influence  of
M. B. Sukkar et al.
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FIG. 1. (a) IL–1b and TNF-a induced GM-CSF release, and (b)
human  airway  smooth  muscle  cell  (ASMC)  density  in
cultures  immediately prior  to  stimulation  with  IL–1b and
TNF-a.  Confluent  human  ASMC  were  pre-incubated  with
either  allergic  asthmatic  serum  (AAS),  non-allergic  non-
asthmatic  serum  (NAS)  or  Monomed™  (a  defined  serum
substitute) for 24h. Cells were serum starved for 24h (striped
bars) or 72h (black bars) prior to stimulation with IL–1b and
TNF-a (10ng/ml  each)  for  24h  (Table  1:  protocol  1).  Bars
represent means±SEM from five cell donors. *p£ 0.05 com-
pared with appropriate Monomed™ control.cell density could be simultaneously assessed (Table
1:  protocol  2). We  found,  that  at  any  given  initial
plating density, IL–1b and TNF-a stimulated GM-CSF
release  in  AAS  treated  cells  was  not  significantly
different  from  that  in  NAS  and  FBS  treated  cells
(p>0.05, n=3).
However,  there was a pattern of  GM-CSF release
that  was  related  to  cell  density.  This  pattern  was
bimodal,  in  that  GM-CSF  release  decreased  as  cell
number increased at initial plating densities between
1´ 104–9´ 104 cells/well.  At  the  highest  density
(2.7´ 105 cells/well),  however,  GM-CSF  production
returned back to the level that was achieved at low
cell density (1´ 104 cells/well) (Fig. 3). This pattern,
however,  was  not  consistently  observed  under  all
serum conditions in all cell donors investigated.
ASMC did not release detectable amounts of IL–5 in
response  to  any  of  the  treatment  conditions  in
protocol 2 (p>0.05, n=3).
Cytokine release by human ASMC pre-treated
with IL-1b/TNF-a prior to stimulation with AAS
ASMC  released  significant  amounts  of  GM-CSF  in
response  to  stimulation  with  IL–1b (10ng/ml)  or
combined stimulation with IL–1b and TNF-a (5, 10,
25ng/ml  each)  under  the  experimental  conditions
used in protocol 3. Detectable levels of GM-CSF were
present in supernatants of cells stimulated with TNF-a
(10ng/ml)  alone,  however,  these  levels  were  not
significantly different from control (Fig. 4).
IL–1b/TNF-a stimulated  ASMC  that  were  subse-
quently  exposed  to  human  serum  (AAS  or  NAS),
released  significantly  greater  amounts  of  GM-CSF
(approximately  3–4  fold  greater)  than  cells  which
were stimulated with IL-1b/TNF-a but subsequently
exposed  to  Monomed™,  the  serum  control.  Sig-
nificant potentiation of GM-CSF release in response to
human  serum  was  observed  following  stimulation
with IL–1b (10ng/ml) or combined stimulation with
IL–1b and TNF-a (5, 10, 25ng/ml each), but not when
the  cells  were  stimulated  with  TNF-a alone.  Fur-
thermore, the amount of GM-CSF released by ASMC
stimulated with IL–1b (10ng/ml) or IL–1b and TNF-a
(10, 25ng/ml) and subsequently  exposed to human
serum was significantly greater than that released by
those same cells in response to IL–1b/TNF-a stimula-
tion alone (Fig. 4).
Indomethacin  did  not  alter  GM-CSF  release  by
ASMC in response to stimulation with IL–1b and TNF-
a (10ng/ml). Further, the level of GM-CSF release in
response  to  AAS,  NAS  or  Monomed™  remained
unaltered, regardless of  whether indomethacin was
present  during  stimulation  with  IL–1b and TNF-a
only, the various serum treatments only, or both IL–
1b and TNF-a and the various serum treatments.
ASMC did not release detectable amounts of IL–5 in
response  to  any  of  the  treatment  conditions  in
protocol 3.
Discussion
It is now recognised that human ASMC synthesize a
wide range of inflammatory mediators in response to
stimulation  with  IL–1b and  TNF-a.  ASMC  in  the
asthmatic state in vivo, however, are not exposed to
IL–1b and TNF-a in isolation. Indeed, the capacity of
ASMC to synthesise cytokines in response to IL–1b
and TNF-a in vivo may be influenced by features of
the allergic asthmatic phenotype.
GM-CSF release by human ASMC in response to IL–
1b/TNF-a has previously been demonstrated.7,8There
have been no studies which have directly measured
IL–5 production by ASMC following stimulation with
Airway smooth muscle cell cytokine production
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FIG.  2.  Relationship  between  cell  number  and  GM-CSF
production. Data were obtained from human ASMC grown
under various serum conditions and then stimulated with IL–
1b and TNF-a (10ng/ml) for 24h (r=0.948; p=0.004).
FIG. 3. IL–1b and TNF-a induced GM-CSF release in human
airway smooth muscle cells plated at 1´ 10
4 (striped bars),
3´ 10
4 (white bars), 9´ 10
4 (black bars) or 2.7´ 10
5 (grey bars)
cells/well  in  either  allergic  asthmatic  serum  (AAS),  non-
allergic non-asthmatic serum (NAS), or foetal bovine serum
(FBS). Cells were serum starved for 24h prior to stimulation
with IL–1b and TNF-a (10ng/ml) for 24h (Table 1: protocol 2).
Bars represent means±SD from triplicate wells of one cell
donor.IL–1b/TNF-a, however, a recent study by Hallsworth
et al.8 supports our finding that ASMC do not release
IL–5 in response to IL–1b/TNF-a. These investigators
demonstrated enhanced in  vitro survival of  human
peripheral  blood  eosinophils  in  response  to  con-
ditioned  medium  from  IL–1b-stimulated  human
ASMC. The survival-enhancing activity of ASMC con-
ditioned  medium  was  completely  inhibited  in  the
presence of antibodies to GM-CSF, whereas antibodies
to IL–5 had no effect. Our study, therefore, confirms
the findings of others with regard to ASMC GM-CSF
release,  and  extends  these  findings  to  show  that
‘allergic  serum  factors’  do  not  influence  GM-CSF
release in response to IL–1b and TNF-a. Furthermore,
this study provides direct evidence that stimulation of
ASMC  with  IL–1b/TNF-a does  not  result  in  IL–5
production,  even  under  experimental  conditions
which attempt to simulate the in vivo environment of
ASMC in allergic asthma.
In examining the effect of AAS on IL–1b and TNF-a
stimulated cytokine release, GM-CSF production was
adjusted for cell number to account for differences in
the  proliferative  effects  of  the  various  serum  treat-
ments  (AAS,  NAS,  Monomed™).  However,  even
though we had corrected for cell number, the data
indicates that cell density may be a factor influencing
GM-CSF production. We therefore modified the exper-
imental  protocol so  that  we  could  control for  cell
density between the various serum treatments at the
time  of  stimulation  with  IL–1b and  TNF-a (see
methods: protocol 2). We found, however, that at any
given cell density, GM-CSF release was similar, regard-
less of whether the cells were exposed to AAS, NAS or
FBS. Thus, even under optimal experimental condi-
tions, we could not demonstrate any influence of AAS
on ASMC cytokine release.
From this study, it appears, that cell density and the
period of serum starvation are at least two aspects of
the  cell  culture  conditions  that  may  influence  the
secretory capacity of ASMC. Indeed, we observed a
trend for greater GM-CSF production in cells serum
starved for 24h as opposed to 72h under all serum
conditions (Fig. 1a). Furthermore, there appeared to
be an inverse relationship between GM-CSF produc-
M. B. Sukkar et al.
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FIG. 4. GM-CSF release by human airway smooth muscle cells stimulated with IL–1b/TNF-a or vehicle for 24h only (striped
bars) or stimulated with IL–1b/TNF-a or vehicle for 24h and subsequently exposed to either allergic asthmatic serum (AAS)
(white bars), non-allergic non-asthmatic serum (NAS) (black bars) or Monomed™ (a defined serum substitute) (grey bars) for
24h (Table 1: protocol 3). Bars represent means±SEM from four to seven cell donors. †p£ 0.05 compared with cytokine vehicle
control. *p£ 0.05 compared with Monomed™ control (grey bars). xp£ 0.05 compared with cells stimulated with IL–1b and TNF-a
only (striped bars).tion  and  cell  density.  However,  given  that  this
relationship was not consistently observed suggests
that other factors may influence the response of the
cells to IL–1b and TNF-a. Thus, although modulation
of GM-CSF release was not demonstrated under the
various  culture  conditions  used  in  this  study,  it  is
possible that AAS modulates ASMC cytokine release
under different conditions.
In this study we also investigated whether IL–1b
and  TNF-a prime  ASMC  to  release  cytokines  in
response to AAS. We found that IL–1b and TNF-a do
prime ASMC to release GM-CSF in response to AAS,
however, this response is not specific to AAS. Indeed,
IL–1b and TNF-a had a similar priming effect in cells
that  were  exposed  to  NAS.  Furthermore,  GM-CSF
released in response to human serum after priming
with  IL–1b/TNF-a (10  or  25ng/ml  each)  was  sig-
nificantly greater than that released in response to IL–
1b and TNF-a exposure only.
Recently, Hakonarson and colleagues reported up-
regulation  of  IL–5  and  IL–1b mRNA  and  protein
synthesis in human ASMC following exposure to AAS
for  24h.  Furthermore,  it  was  shown  that  IL–1b
release in response to AAS was due to the autocrine
action of IL–5.18,19 These investigators also reported
up-regulation of GM-CSF mRNA in response to AAS.18
In this study, we could not demonstrate GM-CSF or
IL–5 release following a 24h exposure to either AAS
or NAS (see methods: protocol 3). It is important to
note, however, that the amount of IL–5 detected in
ASMC supernatants in the studies by Hakonarson et
al.18 was at the limit of detection (10pg/ml) of our
ELISA.
A possible explanation for the discrepancy in the
findings between our study and that of Hakonarson
and colleagues is the difference in the methods used
for  cell  culture.  In  the  study  by  Hakonarson  and
colleagues, human ASMC were grown to confluence
in smooth muscle basal medium supplemented with
5%  FBS  and  serum  starved  in  unsupplemented
medium for 24h before being stimulated with AAS for
a further 24h. In our study, ASMC were seeded at low
density and allowed to incubate for only 24h in 10%
FBS/DMEM,  to  minimise  any  potential  influence  of
variations in cell density. The cells were then serum
starved in Monomed™/DMEM for 24h and exposed
to  10%  AAS/DMEM  for  a  further  24h. Apart  from
minor  variations  in  the  experimental  protocol,  the
main difference is that, in our study, ASMC were non-
confluent,  due  to  the  short  incubation  period  in
growth medium, whereas Hakonarson and colleagues
performed their experiments on confluent cells. This
may  be a  possible explanation  for  the discrepancy.
Another possible explanation is that the concentra-
tion of human AAS to which the cells were exposed
may  have  varied  between  the  two  studies.  In  our
study,  ASMC  were  exposed  to  10%  AAS/DMEM.
Hakonarson and colleagues report  that ASMC were
incubated in AAS but do not specify the concentration
of AAS that was used – if their cells were incubated in
100% AAS then this may be an important methodo-
logical difference between the two studies.
Evidence  that;  (1)  IL–1b is  released  by  human
ASMC in response to AAS19, and that (2) ASMC release
GM-CSF in response to IL–1b, suggests that we should
have observed greater potentiation of GM-CSF release
in AAS vs NAS treated cells, as a consequence of the
release and autocrine action of IL–1b. However, IL–
1b also  induces ASMC  to  release  PGE2
5,6 and,  in
similar  structural  cells,  such  as  human  lung  fibro-
blasts,  PGE2 has  been  reported  to  inhibit  IL–1b
stimulated GM-CSF production.20 Thus, it is possible,
that at  the  time  at  which  GM-CSF  production  was
evaluated,  inhibitory  effects  of  PGE2 on  GM-CSF
release may  have masked any  additional  release  of
GM-CSF in response to AAS. However, this is unlikely,
as  we  did  not  observe  any  modulating  effects  of
indomethacin on serum induced potentiation of GM-
CSF release.
Failure  to  detect any differential  effects  between
AAS and NAS in this study is unlikely  to be due to
‘inactivity’ of the AAS. We recently demonstrated that
exposure of human ASMC to AAS, used at the same
concentration and obtained from the same donor as
this study, results in enhanced release of extracellular
matrix proteins.21 This suggests that the AAS used in
this study is capable of modulating ASMC secretory
function.
In  summary,  we  have  shown  that  IL–1b/TNF-a
prime ASMC to release GM-CSF in response to human
serum.  GM-CSF  promotes  the  survival  and  recruit-
ment of airway inflammatory cells, particularly eosi-
nophils  and  mast  cells.  Our  findings  suggest,  that
through the interaction with IL–1b/TNF-a, ASMC may
play an important role in locally sustaining the airway
inflammatory response in asthma.
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